ClinTec International Awarded Women Business Enterprise Certified Status by WEConnect
News May 10, 2010
ClinTec International, the Global Clinical Research Organization, has been awarded Women Business Enterprise (WBE) certified status by WEConnect Europe - a not-for-profit organization, led by corporate members, that is opening doors to new supply chains for businesses in which women executives hold at least 51 per cent share of ownership.
WEConnect certified status is yet further evidence of ClinTec International’s solid performance and the standing of its President, Founder & CEO, Dr Rabinder Buttar. WBE is awarded after a rigorous certification process – including a specific focus on corporate financials.
Development of a diversity agenda at ClinTec International is very much a current focus, which goes in line with conduct of global projects, cross-border client engagements and an internationally diverse workforce. Certification from WEConnect Europe is in line with this initiative and recognition the important role that Women have to play in the management of modern organizations.
In addition, WEConnect Europe will facilitate ClinTec in building and enhancing a strong network of contacts with other certified companies, forge partnerships with clients who have a diversity agenda, and generate business-to-business tendering opportunities.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE